|
AnGes MG, Seikagaku to Dissolve Joint Development Agreement for NFkB Decoy-Oligo-based Intraarticular Injection |
|
|
|
06 Feb 2006 |
Tokyo, Japan | Feb 06, 2006 | AnGes MG and Seikagaku jointly announced on February 3 that they have agreed to dissolve their agreement on joint development of NF-kappa B decoy oligodeoxynucleotide (NFkB decoy-oligo).
Since August 2002, the two companies have been collaborating in the development of intraarticular injection for treating rheumatism and osteoarthritis.
After evaluating the validity of their joint development efforts, Seikagaku has decided to withdraw from the development project. In the meantime, AnGes MG plans to continue the development of an NFkB decoy-oligo-based intraarticula injection.
SOURCE: AnGes MG |
